<DOC>
	<DOCNO>NCT02412644</DOCNO>
	<brief_summary>12 week open label Otezla® NUVB , follow 6 month double blind Otezla® ( apremilast ) placebo subject obtain PASI 75 week 12 phototherapy</brief_summary>
	<brief_title>Apremilast 30mg Bid With Narrowband UVB Treatment Plaque Psoriasis</brief_title>
	<detailed_description>Primary Objective : To evaluate effectiveness Otezla ( apremilast® ) promote maintenance response subject obtain PASI-75 week 12 phototherapy .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must meet follow criterion enrol study : 1 . Male female adult ≥ 18 year age ; 2 . Diagnosis chronic plaquetype 3 . Moderate severe plaque type psoriasis define baseline : PASI score 12 great , PGA score 3 great BSA affect plaquetype psoriasis 10 % great , 4 . Able willing give write informed consent prior performance studyrelated procedure Subjects meet follow criterion exclude participation study : 1 . Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic , and/or guttate psoriasis ) drug induce psoriasis 2 . Subjects previous exposure apremilast 3 . Malignancy history malignancy , except : treated [ ie , cure ] basal cell squamous cell situ skin carcinoma ; treat [ ie , cure ] malignancy evidence recurrence within previous 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>